Cybrexa Therapeutics
John Houston is a seasoned executive in the biotechnology and pharmaceutical industries, currently serving as the Executive Chairman, President, and CEO of Arvinas since January 2017. Houston's extensive experience includes roles as Chief Scientific Officer at NextCure, Inc., and board memberships at multiple companies, including Cybrexa Therapeutics, Oerth Bio, and BioCT. Previously, Houston held senior positions at Bristol-Myers Squibb from 1998 to 2016, where responsibilities encompassed leadership in disease science research and various biotechnology divisions. Houston's academic credentials include a B.Sc in Medical Microbiology from the University of Glasgow and a Ph.D. in Microbial Biochemistry from Heriot-Watt University.
This person is not in any teams
This person is not in any offices
Cybrexa Therapeutics
1 followers
Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and itwill greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.